INTRODUCTION
The pathogenicity and epidemiology of KI polyomavirus (KIPyV) (species name: human polyomavirus 3 [Polyomaviridae Study Group of the International Committee on Taxonomy of Viruses et al., 2016] ) is poorly understood. First described in 2007 following the screening of a biorepository of nasopharyngeal aspirates [Allander et al., 2007] , numerous retrospective studies assessing the prevalence of the virus in children and adults with symptomatic respiratory infections followed, with reported isolation rates ranging from 0.0% to 6.5% (Supplementary Table SI) . KIPyV is frequently present as a co-infection (33-86% of the time in descriptive studies) and found in immunocompromised individuals, rendering an assessment of its role as a respiratory pathogen difficult (Supplementary Table  SI) . Detailed clinical descriptions of its role as a cause of serious respiratory disease in otherwise healthy children have not been reported to our knowledge. Herein, we describe the complete genome sequence of a KIPyV isolate obtained from an intensive care unit admission in an otherwise healthy 13-month-old boy obtained by unbiased target capture and deep, next-generation sequencing. Concomitantly, the sample was assessed for viral infection of 24 respiratory virus species, covering hundreds of virus subtypes, and strains (Supplementary Table  SII) . A possible co-infection with human bocavirus (HBoV) was detected; however, HBoV viral gene expression was markedly lower than KIPyV gene expression suggesting that KIPyV may have been the causal agent. No additional viral sequences were identified, indicating only the high gene expression of KIPyV and low expression of HBoV. Taken together, our data indicates, in at least certain individuals, that KIPyV infection appears to be capable of causing serious disease in otherwise healthy, immunocompetent children, even those outside the first year of life.
MATERIALS AND METHODS

Sequencing and Phylogenetic Analysis
To identify potential respiratory viral pathogens we used an unbiased, RNA target capture and deep, nextgeneration sequencing approach using a hybridization panel, similar to that reported by Wylie et al. [2015] . The ResVir panel used in this study contains 5,683 hybridization probes of 80 nucleotides in length designed to be complimentary to CDS regions of 24 human respiratory viruses (Supplementary Table SII ) (Dinwiddie, DL in prep) . RNA was isolated from a nasal swab placed in viral transport media using Trizol (ThermoFisher Scientific, Waltham, MA) and the Direct-zol method per manufacturer's recommendations (Zymo Research, Irvine, CA) . A stranded RNAseq library was constructed following the Illumina TruSeq RNA Access protocol and captured using a respiratory virus probe set (ResVir). Paired sequencing (2 Â 75 bp) was conducted on an Illumina MiSeq. Viral sequences were identified by comparison to the KRAKEN metagenomics database [Wood and Salzberg, 2014] and through alignment to a genome reference database of known human viruses using CLC Genomics Workbench (CLC bio, Qiagen, Aarhus, Denmark). To obtain a complete genome of isolate NMKI001, we conducted both alignment-guided consensus sequence generation and de novo assembly using CLC Genomics Workbench (CLC bio, Qiagen). Both methods produced a genome of 5,040 bp with 100% agreement. We used this complete genome to conduct whole genome phylogenetic analysis through nearest neighbor joining with 1,000 bootstraps (CLC Genomics Workbench, Qiagen) to all 15 complete KIPyV genomes available in GenBank at the time of analysis.
Consent
This study was reviewed and approved by the Human Research Review Committee of the University of New Mexico Health Sciences Center (No. 14-294, March 6, 2015) . Written consent was obtained from the parents of the patient prior to collection of the nasal swab.
CASE REPORT AND RESULTS
A 13-month-old, previously healthy Caucasian boy without a previous history of severe infection was admitted to the Pediatric Intensive Care Unit (PICU) at the University of New Mexico Health Sciences Center with respiratory distress following a 5-day history of a febrile cough with wheezing, rhinorrhea, anorexia, and irritability. He was born at term and was otherwise healthy, with no history of prior hospitalizations. The admission occurred in March of 2015 during the peak incidence of seasonal influenza A virus and respiratory syncytial virus infections. He had been seen the morning of admission at an outside facility, where he was found to be non-responsive to a trial of nebulized albuterol and was subsequently referred to the Emergency Department (ED) for further evaluation. His admission examination was notable for hypoxia (oxygen saturation of 87% on room air), tachypnea (respiratory rate of 55), and intercostal retractions, though no wheezing was documented. His admission white blood cell count was 10.5 cells/mm 3 with a normal differential. His chest X-ray on admission revealed bilateral patchy opacities, hyperinflation, and bronchial wall thickening. Clinical testing of a nasopharyngeal swab by PCR for influenza A virus and respiratory syncytial virus were negative. He was admitted to the PICU for worsening respiratory distress and concerns of an impending need for mechanical ventilation. He was febrile for the first day of his hospital stay to a maximum value of 38.4˚C, followed by defervesence with antipyresis. He was initially placed on 3 L oxygen via nasal cannula in the ED, but was rapidly transitioned to high flow nasal cannula shortly after admission for worsening hypoxia, eventually requiring a maximum of 15 L of support. He was never intubated, but was transitioned to nasal cannula after 3 days and to room air the day of discharge. He was discharged home following a 4-day stay in the PICU.
In light of the negative clinical testing for influenza A and respiratory syncytial viruses, we sought to identify the causative agent of his hospitalization. After parental consent, a nasal swab was obtained from the patient. We used an unbiased target capture probe set designed to capture 24 respiratory viral pathogens coupled with deep, next-generation sequencing to detect viral sequences. Viral sequences were identified by comparison to the KRAKEN metagenomics database [Wood and Salzberg, 2014] and through alignment to a genome reference database of known human viruses using CLC Genomics Workbench (CLC bio, Qiagen). Both methods identified a large number of KIPyV sequences and a small minority of HBoV reads (Fig. 1) . Of the 758,060 total Illumina 75 base pair sequencing reads, 423,154 were identified as human (55.8%), 329,948 mapped to KIPyV reference sequence NC_009238 (43.5%), and 4,958 sequencing reads aligned to HBoV genome reference NC_007455 (0.7%) (Fig. 1, Supplementary Table SIII) . Alignment of the viral sequencing reads to their respective RefSeq genomes resulted in 100% coverage of the KIPyV genome, and 20.6% coverage of the HBoV genome (Supplementary Table SIII) . Alignment of sequences to KIPyV RefSeq genome (NC_009238) resulted in mean genome coverage of 4,759Â and the identification of 10 variants, of which 2 were predicted to be non-synonymous (Supplementary Table SIV) .
Whole genome phylogenetic analysis grouped isolate NMKI001 with GM674142 and EF127908 (Fig. 2) , two KIPyV isolates collected from nasopharyngeal aspirates submitted to Karolinska University Laboratory, Stockholm, Sweden [Allander et al., 2007] . Further, analysis of isolates NMKI001 and EF127908 revealed that the two isolates differ from each other by three nucleotides (Supplementary Table SIV) . Two of the three detected variants are predicted to cause amino acid changes (Supplementary Table SIV ). A substitution of T > A at cDNA position 1,482 in the large T antigen is predicted to result in a Histidine to Glutamine change (c.1482T > A; p.His494Gln) and a substitution of T > A in the small T antigen at cDNA position 312 is predicted to cause an Aspartic acid to be replaced with a Glutamic acid (c.312T > A; p.Asp104Glu). The whole-genome sequence of isolate NMKI001 has been deposited in GenBank under the accession number KU746835.
DISCUSSION
Studies are conflicting with regards to the association of human polyomavirus 3 with symptomatic disease, particularly in otherwise healthy children. Detailed descriptions of otherwise healthy children with severe lower respiratory tract illness due to KIPyV have not been reported to our knowledge. Previous reports of children with KIPyV infections have lacked an assessment of the severity of illness, description of medical co-morbidities, thorough assessment of potential viral, and bacterial co-infections [Babakir-Mina et al., 2008; Foulongne et al., 2008; Yuan et al., 2008; Rao et al., 2011] and complete genome sequence analysis of the virus. Descriptions of its role in patients with medical co-morbidities are better described. Detection of KIPyV has been reported in stem cell/bone marrow transplant patients [Kuypers et al., 2012; Siebrasse et al., 2012] , hematology/oncology patients [Rao et al., 2011 ], a Fig. 1 . Percent of sequencing reads identified through alignment to a genome reference database of known human viruses (A) and using alignment to the KRAKEN metagenomics database [Wood and Salzberg, 2014] (B). child with severe combined immunodeficiency [Falcone et al., 2012] , children with human immunodeficiency virus (HIV) infection [Nunes et al., 2014] and one patient with chronic lung disease and congestive heart failure associated with a congenital cardiac defect [Ren et al., 2009] . Of note, the presence of persistently high viral loads of KIPyV were found in the nasopharynx of a 17-month-old child who died of respiratory failure within 4 months of a bone marrow transplant for Fanconi anemia [Siebrasse et al., 2012] . Immunohistochemical staining of lung tissue on autopsy demonstrated the presence KIPyV, with CD68-positive alveolar macrophages representing approximately half of all infected cells [Siebrasse et al., 2014] . KIPyV has also been demonstrated from immunohistochemical staining of lung and splenic tissue from an HIV infected patient [Siebrasse et al., 2014] . Other studies, however, have not documented any increased association of the virus with symptomatic respiratory infections among subjects with and without immunocompromising conditions [Norja et al., 2007; Van de Pol et al., 2009] .
The seroprevalence of KIPyV has been reported to be as high as 55-90%, with two studies demonstrating rates above 90% in children 5-19 years [Nguyen et al., 2009] and adults [Gossai et al., 2016] , indicating widespread infection with the virus. Interestingly, acquisition of the virus may occur early in life, with prospective data from a birth cohort in Australia demonstrating primary infection around 12 months of age [Rockett et al., 2015] . Prolonged shedding of the virus in children has also been described [Van der Zalm et al., 2008] . Human polyomavirus 3 has also been isolated from up to 6.5% of children with symptomatic respiratory infections [Mourez et al., 2009] . Together, this suggests, at a minimum, a role for the virus as a frequent cause of asymptomatic infections, though potential virulence is obviously quite possible, particularly in specific cohorts. However, given the high rate of co-detection of other potential respiratory pathogens [Wattier et al., 2008] , the high seroprevalence of the virus in healthy adults and the frequency with which it is isolated from asymptomatic individuals, its role as a pathogen still awaits more formal confirmation.
Previous complete genome sequencing of KIPyV has revealed a highly conserved genome with minimal genomic variation [Bialasiewicz et al., 2007] . Isolate NMKI001 is different from all previously reported genomes and contains two amino acid differences as compared to the closest virus isolate, Stockholm 380 (EF127908). It is possible that variation within the large and small T antigens may impact virulence, such as antibody recognition or infectivity; however, additional research is needed to evaluate.
Given the limited commercial availability of viral diagnostic tests to detect KIPyV, it is likely that the full spectrum of clinical pathology associated with the virus has yet to be described. Clinical symptoms reported in the literature with KIPyV are not distinct from those seen with common viral respiratory pathogens either, which would also render attempts to characterize the virus without widespread testing challenging [Bialasiewicz et al., 2008; Rao et al., 2011] . We recently, reported the complete genome sequence of a novel isolate of WU polyomavirus (WUPyV) obtained from a nasopharyngeal sample taken from a patient with acute respiratory symptoms [Dinwiddie et al., 2016] . Through our studies and others, it is clear that both KIPyV and WUPyV have been detected in individuals with respiratory symptoms, however, their respective role in the clinical manifestations is still unclear. Nonetheless, whether the polyomaviruses are able to cause clinical symptoms in immunocompetent individuals as the sole pathogen or only as part of a co-infection will require further investigation into their epidemiology, genomics, and pathogenicity. Lastly, though the ResVir panel provides an accurate and sensitive assessment for a large number of viruses, the possibility of other potential viral agents eluding detection cannot be excluded.
In conclusion, we report the first detailed clinical description of severe lower respiratory tract infection with KIPyV in an otherwise healthy child. Further, we were able to generate a complete genome sequence of this isolate and conduct detailed phylogenetic analysis of the virus. We demonstrate that the isolate from New Mexico is distinct from all previously sequenced KIPyV genomes despite the polyomaviruses having a highly conserved dsDNA genome. Providers should consider this diagnosis in hospitalized children with negative results on standard viral diagnostic assays.
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